MedTrace Logo

Determining the Pharmacogenetic Basis of Non-responsiveness to the Sedative Effects of Dexmedetomidine in Children

NCT04471402 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-03-16

No results posted yet for this study

Summary

Intranasal Dexmedetomidine is one of the sedative drugs of choice commonly used as an anxiolytic premedication for children for diagnostic or therapeutic procedures. However, some children do not achieve the level of sedation expected with the usual dose after an expected timeframe, leading to distress and costly time wasted.

In this study, we would try to identify a genetic basis to non-responders of Dexmedetomidine by comparing a chosen gene panel of 250 relevant genes between responders and non-responders to a standardized 3mcg/kg intranasal Dexmedetomidine.

Conditions

  • Pharmacogenetic Study
  • Procedural Anxiety
  • Dexmedetomidine

Interventions

DRUG

Precedex

Intranasal Precedex 3mcg/kg

Sponsors & Collaborators

  • Hong Kong Children's Hospital

    lead OTHER

Principal Investigators

  • Vivian MY Yuen, M.D. · Hong Kong Children's Hospital

Eligibility

Min Age
6 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04471402 on ClinicalTrials.gov